Jointly Provided by AKH, Inc. and peerXchange, Inc.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
The progressive fibrotic interstitial lung disease subtypes of IPF and SSc-ILD share common diagnostic and management challenges. There is at present no cure for IPF or SSc-ILD and existing treatments focus on delaying disease progression, controlling symptoms and preventing complications. The management of IPF and SSc-ILD continues to evolve and clinicians are challenged to stay abreast of current guidelines, evidence supporting the use of antifibrotics in practice, and advances from recent clinical studies or drug approvals. Collaborative decision-making that involves the patient and their caregivers is critical in developing treatment plans for patients with IPF and SSc-ILD.
In this series of four podcasts, Joseph D. Zibrak, MD and Lesley Anne Saketkoo, MD, MPH, collaborate to explore a range of clinical challenges, practice pearls and questions associated with the treatment of IPF and SSc-ILD and that are germane to clinicians who provide care to patients with progressive fibrotic interstitial lung diseases.
Each podcast is designated for AMA PRA Category 1 Credits™ thereby enabling clinicians to participate in one or more podcasts. Clinician guides for each podcast are available for download or print and include a podcast transcript, clinician and patient resources, and a bibliography of suggested reading.
Estimated Time to Complete Activities: 2.5 hours (for completing all 4 activities)